← All Co-diagnostics, INC filings

Co-diagnostics, INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
CODX
Co-diagnostics, INC
DEF: Co-Diagnostics Sets Annual Meeting Date, Proposes Equity Plan Increase
Co-Diagnostics, Inc. announced its 2026 Annual Meeting of Shareholders, scheduled for September 3, 2026, and is seeking shareholder approval to increase the number of shares available under its 2025 Equity Incentive Plan.
NASDAQ
CODX
Co-diagnostics, INC
DEF: Co-Diagnostics Seeks Shareholder Approval for Reverse Stock Split
Co-Diagnostics, Inc. will hold a Special Meeting on December 5, 2025, to seek shareholder approval for a reverse stock split to maintain its Nasdaq listing.
NASDAQ
CODX
Co-diagnostics, INC
DEF: Co-Diagnostics Seeks Shareholder Approval for 2025 Equity Incentive Plan and Director Elections
Co-Diagnostics is holding its annual shareholder meeting on May 28, 2025, to vote on director elections, adoption of a new equity incentive plan, executive compensation, and ratification of the company's accounting firm.
NASDAQ
CODX
Co-diagnostics, INC
DEF 14A: Co-Diagnostics, Inc. Announces Annual Shareholder Meeting and Proxy Statement
Co-Diagnostics, Inc. will hold its virtual-only Annual Meeting of Shareholders on August 29, 2024, to vote on director election, executive compensation, auditor ratification, and other business.